BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 18548091)

  • 1. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.
    Emanuel PD
    Leukemia; 2008 Jul; 22(7):1335-42. PubMed ID: 18548091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
    Hall J; Foucar K
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.
    Niemeyer CM; Kratz CP
    Br J Haematol; 2008 Mar; 140(6):610-24. PubMed ID: 18302710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment advances for pediatric and adult onset neoplasms with monocytosis.
    McCullough KB; Kuhn AK; Patnaik MM
    Curr Hematol Malig Rep; 2021 Jun; 16(3):256-266. PubMed ID: 33728588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMML: a biologically distinct myeloproliferative disease.
    Cortes J
    Curr Hematol Rep; 2003 May; 2(3):202-8. PubMed ID: 12901341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed myeloproliferative and myelodysplastic disorders.
    Emanuel PD
    Curr Hematol Malig Rep; 2007 Feb; 2(1):9-12. PubMed ID: 20425383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined.
    Elliott MA
    Best Pract Res Clin Haematol; 2006; 19(3):571-93. PubMed ID: 16781489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myelomonocytic leukemia: lost in classification?
    Bowen DT
    Hematol Oncol; 2005 Mar; 23(1):26-33. PubMed ID: 16149105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Juvenile myelomonocytic leukemia.
    Emanuel PD
    Curr Hematol Rep; 2004 May; 3(3):203-9. PubMed ID: 15087069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML).
    Hasle H; Baumann I; Bergsträsser E; Fenu S; Fischer A; Kardos G; Kerndrup G; Locatelli F; Rogge T; Schultz KR; Starý J; Trebo M; van den Heuvel-Eibrink MM; Harbott J; Nöllke P; Niemeyer CM;
    Leukemia; 2004 Dec; 18(12):2008-14. PubMed ID: 15496981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case-control study of chronic myelomonocytic leukemia (CMML) in Shanghai, China: evaluation of risk factors for CMML, with special focus on benzene.
    Gross SA; Irons RD; Scott PK; Galbraith D; Wang XQ; Chen Y; Paustenbach D
    Arch Environ Occup Health; 2012; 67(4):206-18. PubMed ID: 23074978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
    Koike K; Matsuda K
    Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
    Cervera N; Itzykson R; Coppin E; Prebet T; Murati A; Legall S; Vey N; Solary E; Birnbaum D; Gelsi-Boyer V
    Am J Hematol; 2014 Jun; 89(6):604-9. PubMed ID: 24595958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myelomonocytic leukemia: myeloproliferative variant.
    Onida F; Beran M
    Curr Hematol Rep; 2004 May; 3(3):218-26. PubMed ID: 15087071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAS pathway mutations in juvenile myelomonocytic leukemia.
    Emanuel PD
    Acta Haematol; 2008; 119(4):207-11. PubMed ID: 18566538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.
    Romano M; Della Porta MG; Gallì A; Panini N; Licandro SA; Bello E; Craparotta I; Rosti V; Bonetti E; Tancredi R; Rossi M; Mannarino L; Marchini S; Porcu L; Galmarini CM; Zambelli A; Zecca M; Locatelli F; Cazzola M; Biondi A; Rambaldi A; Allavena P; Erba E; D'Incalci M
    Br J Cancer; 2017 Jan; 116(3):335-343. PubMed ID: 28072764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical management of chronic myelomonocytic leukemia.
    Padron E; Komrokji R; List AF
    Clin Adv Hematol Oncol; 2014 Mar; 12(3):172-8. PubMed ID: 24927265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.
    Orazi A; Germing U
    Leukemia; 2008 Jul; 22(7):1308-19. PubMed ID: 18480833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
    Rudelius M; Weinberg OK; Niemeyer CM; Shimamura A; Calvo KR
    Virchows Arch; 2023 Jan; 482(1):113-130. PubMed ID: 36445482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.